Investing in 2010: Five Biotechs Under $5


As the year ends with markets staging a remarkable nine-month recovery, posting what may be the best yearly gains since 2003, some investors' appetites for risk may increase. And there's no better place to find that risk-reward potential than in the biotech sector. Recent dealmaking in that area, from acquisitions of small biotechs by Big Pharma to key licensing pacts, have put the spotlight on biotech, and that will probably continue, as Big Pharma tries to avoid losses from the fast-approaching "patent cliff."